https://orcid.org/0000-0001-7186-0049
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Raveendra KR, Chirag Rathod, Rahul Darnule, Subramanian Loganathan, Sarika Deodhar, Radhika A, Ashwani Marwah, Nitin M Chaudhari, Binay K Thakur, Sivakumar Vaidyanathan & Sandeep Nilkanth Athalye. (2023) REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT. Expert Opinion on Biological Therapy 23:5, pages 443-454.
Read now
Read now
Jingjing Zhang, Han Zhang & Litao Sun. (2022) Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. mAbs 14:1.
Read now
Read now
Suresh Kumar, Rosemarie De Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah & Sandeep N. Athalye. (2021) A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opinion on Biological Therapy 21:5, pages 675-686.
Read now
Read now
Articles from other publishers (18)
Mradul Kumar Daga, Siddharth Chand, Naresh Kumar, Govind Mawari, R. V. Raghu & J. Aarthi. 2023. Coronaviruses: Volume 3. Coronaviruses: Volume 3
49
78
.
Priyancka Arora, Vaishnavi Singh & Ajay Kumar. 2023. Biomanufacturing for Sustainable Production of Biomolecules. Biomanufacturing for Sustainable Production of Biomolecules
297
313
.
Thiago L. Machado, Alanna C. Santos, Tamiris Azamor, Andrea M. V. da Silva, Vanessa R. Pimenta, Luciana N. Tubarão, Alexandre dos Santos da Silva, Daniela Del Rosário Flores Rodrigues, Rodrigo Müller, Marcelo A. Pinto, Livia M. Villar, Ana P. A. Bom & Juliana G. Melgaço. (2022) CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID‐19 therapy. Journal of Medical Virology 95:1.
Crossref
Crossref
Gandarvakottai Senthilkumar Arumugam, Kannan Damodharan, Mukesh Doble & Sathiah Thennarasu. (2022) Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. Molecular Biomedicine 3:1.
Crossref
Crossref
Youssef Ait Hamdan, Fatima El Amerany, Jacques Desbrières, Abdessadek Aghrinane, Hassane Oudadesse & Mohammed Rhazi. (2022) The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic. Polymer Bulletin.
Crossref
Crossref
Zahra Malekinejad, Amir Baghbanzadeh, Ailar Nakhlband, Behzad Baradaran, Sevda Jafari, Yasin Bagheri, Faezeh Raei, Soheila Montazersaheb & Raheleh Farahzadi. (2022) Recent clinical findings on the role of kinase inhibitors in COVID-19 management. Life Sciences 306, pages 120809.
Crossref
Crossref
Qiwei Qian, Nana Cui, Bingyuan Huang, Yudong Zhao, Qiaoyan Liu, Mingli Hu, Bo Li, Qixia Wang, Qi Miao, Zhengrui You, Xiong Ma & Ruqi Tang. (2022) Intrahepatic activated leukocyte cell adhesion molecule induces CD6highCD4+ T cell infiltration in autoimmune hepatitis. Frontiers in Immunology 13.
Crossref
Crossref
Vyankatesh Pidiyar, Ganesh Kumraj, Kafil Ahmed, Syed Ahmed, Sanket Shah, Piyali Majumder, Bhawna Verma, Sarang Pathak & Sushmita Mukherjee. (2022) COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries. Vaccine 40:36, pages 5302-5312.
Crossref
Crossref
Jacek Plichta, Piotr Kuna & Michał Panek. (2022) Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents. COVID 2:5, pages 599-620.
Crossref
Crossref
Benedetta Rambaldi, Haesook T. Kim, Yohei Arihara, Takeru Asano, Carol Reynolds, Mariah Manter, Max Halpern, Augustine Weber, John Koreth, Corey Cutler, Mahasweta Gooptu, Sarah Nikiforow, Vincent T. Ho, Joseph H. Antin, Rizwan Romee, Jeanette Ampudia, Cherie Ng, Stephen Connelly, Robert J. Soiffer & Jerome Ritz. (2022) Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. Haematologica 107:11, pages 2617-2629.
Crossref
Crossref
Abdolreza Esmaeilzadeh, Samaneh Rostami, Pegah M. Yeganeh, Safa Tahmasebi & Majid Ahmadi. (2021) Recent advances in antibody‐based immunotherapy strategies for COVID‐19. Journal of Cellular Biochemistry 122:10, pages 1389-1412.
Crossref
Crossref
Karolina Piotrowicz, Jerzy Gąsowski, Jean-Pierre Michel & Nicola Veronese. (2021) Post-COVID-19 acute sarcopenia: physiopathology and management. Aging Clinical and Experimental Research 33:10, pages 2887-2898.
Crossref
Crossref
Kavita Manchanda, Jasbir Singh, Ranjeev Bhagat, Ilmjot Kaur Tiwana & Harmanjit Singh. (2021) Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. International Journal of Risk & Safety in Medicine 32:1, pages 3-17.
Crossref
Crossref
Hardeep Kaur, Manpreet Kaur, Anusuya Bhattacharyya, Manisha Prajapat, Prasad Thota, Phulen Sarma, Subodh Kumar, Gurjeet Kaur, Saurabh Sharma, Ajay Prakash, PK Saifuddin & Bikash Medhi. (2021) Indian contribution toward biomedical research and development in COVID-19: A systematic review. Indian Journal of Pharmacology 53:1, pages 63.
Crossref
Crossref
SM Baruah. (2021) Newer medications in coronavirus disease-2019 (COVID-19) infection. Assam Journal of Internal Medicine 11:2, pages 1.
Crossref
Crossref
Shubham Atal, Zeenat Fatima & Sadasivam Balakrishnan. (2020) Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?. BioDrugs 34:6, pages 705-711.
Crossref
Crossref
Pugazhenthan Thangaraju, Nanditha Venkatesan, Eswaran Thangaraju & Sajitha Venkatesan. (2020) Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era. SN Comprehensive Clinical Medicine 2:11, pages 2131-2136.
Crossref
Crossref
Armando Caballero, Lázaro M Filgueira, Julio Betancourt, Naivy Sánchez, Carlos Hidalgo, Alberto Ramírez, Alejandro Martinez, Rolando E Despaigne, Alberto Escalona, Henrry Diaz, Elio Meriño, Lilia M Ortega, Ulises Castillo, Mayra Ramos, Danay Saavedra, Yanelda García, Geydi Lorenzo, Meylán Cepeda, Maylén Arencibia, Leticia Cabrera, Milagros Domecq, Daymys Estévez, Carmen Valenzuela, Patricia Lorenzo, Lizet Sánchez, Zaima Mazorra, Kalet León & Tania Crombet. (2020) Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab. Clinical & Translational Immunology 9:11.
Crossref
Crossref